| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3848276 | American Journal of Kidney Diseases | 2013 | 11 Pages |
Abstract
DES use in patients with eGFR <60 mL/min/1.73 m2 is associated with a reduced rate of repeat revascularization and myocardial infarction without increased risk of stent thrombosis. The true effect of DESs versus BMSs on mortality needs to be confirmed by randomized controlled trials.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Zhi Jian MD, PhD, Kishore J. MD, Chetan MBBS, Fei MD, Dong Mei MD, Yu Yang MD, Ying Xin MD, Yu Jie MD, PhD,